TARA - Protara stock surges ~10% on FDA clearance to start trial of rare disease drug
2023-05-02 08:46:59 ET
- Protara Therapeutics ( NASDAQ: TARA ) received clearance from the U.S. Food and Drug Administration (FDA) to start a trial of TARA-002 to treat children with a rare disease called lymphatic malformations (LMs).
- LMs are non-cancerous vascular lesions made of fluid-filled spaces (cysts) which potentially occurs due to abnormal development of the lymphatic system.
- The phase 2 study , dubbed STARBORN-1, is expected to start in Q4 2023 and will evaluate intracystic injection of TARA-002 to treat macrocystic and mixed cystic LMs in children six months to less than 18 years of age.
- TARA-002 has been previously granted rare pediatric disease designation by the FDA for treating LMs.
- TARA +12.91% to $3.41 premarket May 2
For further details see:
Protara stock surges ~10% on FDA clearance to start trial of rare disease drug